老年肿瘤微环境对免疫检查点抑制剂治疗的影响

doi:10.16352/j.issn.1001-6325.2025.09.1139

基础医学与临床 ›› 2025, Vol. 45 ›› Issue (9): 1139-1143.doi: 10.16352/j.issn.1001-6325.2025.09.1139

老年肿瘤微环境对免疫检查点抑制剂治疗的影响

周慧聪¹, 邵亚娟^2*

1.郑州大学第二附属医院消化内科,郑州河南 450014;
2.中国医学科学院北京协和医学院北京协和医院肿瘤内科,北京 100730

收稿日期:2025-03-06 修回日期:2025-06-27 出版日期:2025-09-05 发布日期:2025-08-27
通讯作者: ^*shaoyj@pumch.cn
基金资助:
北京协和医院中央高水平医院临床研究专项(2022-PUMCH-B-049)

Impact of the aging tumor microenvironment on immune checkpoint inhibitors therapy

ZHOU Huicong¹, SHAO Yajuan^2*

1. Department of Gastroenterology,the Second Affiliated Hospital of Zhengzhou University, Zhengzhou 450014;
2. Department of Oncology, Peking Union Medical College Hospital, CAMS & PUMC, Beijing 100730, China

Received:2025-03-06 Revised:2025-06-27 Online:2025-09-05 Published:2025-08-27
Contact: ^*shaoyj@pumch.cn

摘要/Abstract

摘要： 肿瘤微环境(TME)在肿瘤发生和进展中的作用越来越引起重视,本综述阐述衰老对肿瘤微环境中免疫细胞的功能、细胞外基质、血管、细胞因子、代谢产物的影响,这种影响可能会改变宿主对免疫检查点抑制剂(ICIs)的反应,依据最新临床研究结果来评估老年肿瘤患者应用ICIs的安全性和不良反应。

关键词: 肿瘤微环境, 细胞外基质, 衰老, 免疫检查点抑制剂

Abstract: The role of tumor microenvironment(TME) in tumor genesis and progression has attracted increasing attention. This review describes the effects of aging on the function of immune cells, extra cellular matrix, vasculature, cytokines, and metabolites in the tumor microenvironment, which may alter the host's response to immune checkpoint inhibitors (ICIs) and relies on the results of the most recent clinical studies to evaluate the safety of ICIs for elderly oncology patients and potential adverse effects.

Key words: tumor microenvironment, extracellular matrix, aging, immune checkpoint inhibitors

中图分类号:

周慧聪, 邵亚娟. 老年肿瘤微环境对免疫检查点抑制剂治疗的影响[J]. 基础医学与临床, 2025, 45(9): 1139-1143.

ZHOU Huicong, SHAO Yajuan. Impact of the aging tumor microenvironment on immune checkpoint inhibitors therapy[J]. Basic & Clinical Medicine, 2025, 45(9): 1139-1143.

参考文献 30

[1]	郑荣寿, 陈茹,韩冰峰,等. 2022年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志,2024,46:221-231.
[2]	Aunan JR, Cho WC, Soreide K. The biology of aging and cancer: a brief overview of shared and divergent molecular hallmarks[J]. Aging Dis, 2017, 8:628-642.
[3]	Fane M, Weeraratna AT. How the ageing microenviron-ment influences tumour progression[J]. Nat Rev Cancer,2020,20:89-106.
[4]	Pilley SE, Esparza E, Mullen PJ. The aging tumor metabolic microenvironment[J]. Curr Opin Biotechnol,2023,84:102995-103002.
[5]	Zhao BH, Wu B, Feng N, et al. Aging microenvironment and antitumor immunity for geriatric oncology: the landscape and future implications[J]. J Hematol Oncol, 2023, 16:27-34.
[6]	Binnewies M, Roberts EW, Kersten K,et al. Understand-ing the tumor immune microenvironment (TIME) for effective therapy[J]. Nat Med, 2018, 24:541-550.
[7]	Daste A, Domblides C, Gross-Goupil M, et al. Immune checkpoint inhibitors and elderly people: a review[J]. Eur J Cancer, 2017, 82:155-166.
[8]	Jackaman C, Tomay F, Duong L, et al. Aging and cancer: the role of macrophages and neutrophils[J]. Ageing Res Rev, 2017, 36:105-116.
[9]	Tang T, Huang X, Zhang G, et al. Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy[J]. Signal Transduct Target Ther, 2021, 6:72-85.
[10]	Chen S, Saeed AFUH, Liu Q, et al. Macrophages in immunoregulation and therapeutics[J]. Signal Transduct Target Ther, 2023, 8:207-242.
[11]	Kawashima S, Togashi Y. Resistance to immune check-point inhibitors and the tumor microenvironment[J]. Exp Dermatol, 2023, 32:240-249.
[12]	Ohtani N. The roles and mechanisms of senescence-associated secretory phenotype (SASP): Can it be controlled by senolysis?[J]. Inflamm Regen, 2022, 42:11-19.
[13]	Liu JY, Liu JY, Qin GH, et al. MDSCs-derived GPR84 induces CD8+T-Cell senescence via P53 activation to suppress the antitumor response[J]. J Immunother Cancer, 2023, 11:e007802-e007816.
[14]	Sidharth SJ, Giselle BS, Harry S, et al. The role of aging and senescence in immune checkpoint inhibitor response and toxicity[J]. Int J Mol Sci, 2024, 25:7013-7023.
[15]	Hynes RO. The extracellular matrix: not just pretty fibrils[J]. Science, 2009, 326:1216-1219.
[16]	Ontiveros CO, Murray CE, Crossland G, et al. Considerations and approaches for cancer immunotherapy in the aging host[J]. Cancer Immunol Res, 2023, 11:1449-1461.
[17]	Coppé JP, Desprez PY, Krtolica A, et al.The senescence-associated secretory phenotype: the dark side of tumor suppression[J]. Annu Rev Pathol, 2010:5:99-118.
[18]	Lau L, Porciuncula A, Yu A, et al. Uncoupling the senescence-associated secretory phenotype from cell cycle exit via interleukin-1 inactivation unveils its protumori-genic role[J]. Mol Cell Biol, 2019, 39:e00586-e00604.
[19]	Folkman J. Tumor angiogenesis: therapeutic implications[J]. N Engl J Med, 1971, 285:1182-1186.
[20]	Ruscetti M, Morris JP, Mezzadra R, et al. Senescence-induced vascular remodeling creates therapeutic vulner-abilities in pancreas cancer[J]. Cell, 2020, 181:424-441.e21.
[21]	Ramasamy SK, Kusumbe AP, Schiller M, et al. Blood flow controls bone vascular function and osteogenesis[J]. Nat Commun, 2016, 7:13601-136014.
[22]	Gu J, Zhou J, Chen Q, et al. Tumor metabolite lactate promotes tumorigenesis by modulating MOESIN lactylation and enhancing TGF-β signaling in regulatory T cells[J]. Cell Rep, 2022, 39:110986-111004.
[23]	Noe JT, Rendon BE, Geller AE, et al. Lactate supports a metabolic-epigenetic link in macrophage polarization[J]. Sci Adv, 2021, 7:8602-8614.
[24]	Brand A, Singer K, Koehl GE, et al. LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK cells[J]. Cell Metab, 2016, 24:657-671.
[25]	Kopinski PK, Singh LN, Zhang S, et al. Mitochondrial DNA variation and cancer[J]. Nat Rev Cancer, 2021, 21:431-445.
[26]	Gomes AP, Ilter D, Low V, et al. Age-induced accumulation of methylmalonic acid promotes tumour progression[J]. Nature, 2020, 585:284-287.
[27]	Wong SK, Nebhan CA, Johnson DB. Impact of patient age on clinical efficacy and toxicity of checkpoint inhibitor therapy[J].Front Immunol, 2021, 12, 786046-786054.
[28]	Pawelec G. Does patient age influence anti-cancer immunity?[J]. Semin Immunopathol, 2019, 41:125-131.
[29]	Baldini C, Martin Romano P, V oisin AL, et al. Impact of aging on immune-related adverse events generated by anti-programmed death (ligand)PD-(L)1 therapies[J]. Eur J Cancer, 2020, 129:71-79.
[30]	Maria FS, Andrea A, Peio A, et al. New perspectives in cancer immunotherapy: targeting IL-6 cytokine family[J]. J Immunother Cancer, 2023, 11: e007530-e007543.

老年肿瘤微环境对免疫检查点抑制剂治疗的影响

Impact of the aging tumor microenvironment on immune checkpoint inhibitors therapy

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 30

相关文章 15

编辑推荐

Metrics

本文评价

[1]	龙丽娟, 宋松泽, 叶棋浓, 蔺静. LSD1调控肿瘤免疫机制的研究进展[J]. 基础医学与临床, 2025, 45(8): 1088-1092.
[2]	印华润, 赵宁, 吴志远, 李拥军, 尹洪超. 皮肤桥蛋白通过IL-1β-COL1A1轴促进腹主动脉瘤发展[J]. 基础医学与临床, 2025, 45(7): 918-925.
[3]	陆晓萱, 郭丽娜, 张红, 宋婉璐, 胡宇飞, 杨沛然. 内皮细胞增殖及细胞外基质相关通路调控模型大鼠动脉性肺动脉高压[J]. 基础医学与临床, 2025, 45(6): 770-776.
[4]	陈运华, 李迪, 赵晓妍, 陈明, 李红凌, 赵春华. 敲降人组织特异性lncRNA MEK6-AS1改善衰老间充质干细胞成骨分化能力[J]. 基础医学与临床, 2025, 45(5): 568-574.
[5]	李云帆, 邹佳铭, 王钰铖, 鞠瑞, 郭磊. CTO抑制小鼠胶质瘤细胞原位生长并调节相关小胶质细胞代谢及炎性表型[J]. 基础医学与临床, 2025, 45(4): 478-485.
[6]	叶敏, 郭秀英, 王丹心, 何光亮. 抗衰老 Klotho 基因在炎性反应和纤维化中的作用[J]. 基础医学与临床, 2025, 45(10): 1382-1386.
[7]	刘保清, 黄容, 卢艳, 李凯, 张宁, 刘长征, 宋伟. 胃癌类器官在基础研究与临床应用中的进展[J]. 基础医学与临床, 2024, 44(9): 1219-1222.
[8]	李阳, 朱蕾. 真核延伸因子2激酶是治疗肿瘤的潜在新靶标[J]. 基础医学与临床, 2024, 44(7): 1039-1043.
[9]	龚金涛, 厉建伟, 李玉恒, 李堑, 赵春华. 骨髓间充质干细胞缓解模拟微重力对小鼠大脑皮质的不利影响[J]. 基础医学与临床, 2024, 44(6): 772-778.
[10]	高竞溪, 赵晓妍, 朱星雨, 孙昭, 韩钦, 赵春华. BM-MSCs延缓CD8⁺初始T细胞衰老[J]. 基础医学与临床, 2024, 44(5): 683-689.
[11]	魏丹丹, 宋宇涵, 王淇, 宿树兰, 朱悦, 段金廒. 年龄相关性黄斑变性的研究进展[J]. 基础医学与临床, 2024, 44(4): 553-557.
[12]	代娣, 刘玉琴. 原发性胃淋巴瘤的诊断难点及治疗进展[J]. 基础医学与临床, 2023, 43(9): 1462-1466.
[13]	张海灵, 杨玉, 周倩倩, 汪远金, 王婷. 微囊藻毒素-LR处理的中性粒细胞NETs促进结直肠癌细胞迁移[J]. 基础医学与临床, 2023, 43(6): 967-973.
[14]	柴亚如, 邓玉婷, 戴红艳, 管军. Klotho在心力衰竭中作用的研究进展[J]. 基础医学与临床, 2023, 43(6): 998-1002.
[15]	卢琰, 周雅博, 陈洁. 利用类器官培养构建小鼠肝脏衰老模型[J]. 基础医学与临床, 2023, 43(4): 554-559.